Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tetrodotoxin (Primary)
  • Indications Chemotherapy-induced damage; Neuropathic pain
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HALT-CINP
  • Sponsors Dogwood Therapeutics

    • Most Recent Events

    • 31 Mar 2025 According to Dogwood Therapeutics media release, the company commenced commenced dosing of patients in this sudy.
    • 18 Mar 2025 trial event According to Dogwood Therapeutics media release, company is aiming to recruit 100 patients with CINP by the fourth quarter of 2025,to execute an interim analysis on the HALT-CINP trial in the fourth quarter of 2025.
    • 18 Mar 2025 According to Dogwood Therapeutics media release, first patient has been dosed in this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top